Supply Chain Intelligence

Savara Inc. Supply Chain

SVRA supply chain intelligence for Savara Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.

SVRA ·Last updated 2026-07-30 · Interactive map →

Data compiled by Redley Lamar · ChainSifter Intelligence

8Suppliers
0Customers
3Debt Items
20Related Chains

Savara Inc. Suppliers

TickerNameConfidenceEvidence
ML7-YARDLEY-PARTNERS-LP ML7-YARDLEY-PARTNERS-LP 92% On March 10, 2026, Savara Inc. (the “Company”) entered into an Agreement of Lease (the “Lease”) with ML7 Yardley Partners, LP (“Landlord”), pursuant to which the Company will lease approximately 10,7…
PARI PARI 92% We also have a commercial supply agreement with PARI (the “PARI Supply Agreement”) related to the supply of the PARI eFlow ® Nebulizer System and related accessories for commercial use with our produ…
GEMA GEMA 90% the Company shall pay GEMA a royalty equal to low-single digits of the net sales in that country
THIRD-PARTY-CMOS THIRD-PARTY-CMOS 90% For clinical and commercial supplies, if approved, we have supply agreements with third party CMOs for drug substance, finished drug product, drug delivery devices and other necessary components of o…
RTW-INVESTMENTS-LP RTW-INVESTMENTS-LP 80% The First Amendment grants the Lenders a first-priority perfected security interest in the Company’s intellectual property that will convert to a negative pledge if the Company terminates the Purchas…
SVB-LOAN SVB-LOAN 80% As of March 31, 2026, approximately $ 0.4 million of fees consisting of legal, commitment and facility charges, paid to the Lenders were capitalized
TMO Thermo Fisher Scientific Inc. 72% primary and secondary drug substance manufacturing partners. The primary drug substance manufacturer is GEMA Biotech S.A. (“GEMA”). In February 2024, we announced entry into a Master Services Agreeme…
TMO Thermo Fisher Scientific Inc. 72% Reciprocal relationship from TMO graph: Reciprocal relationship from SVRA graph: primary and secondary drug substance manufacturing partners. The primary drug substance manufacturer is GEMA Biotech S…

Savara Inc. Customers

No clients on recordNo downstream customers found in our database for Savara Inc..

Savara Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
SVRA-DEBT-12839 Xbrl Convertible 90% xbrl convertible detail from xbrl 2017-12-31.
SVRA-DEBT Debt stack $30.1M 90% Market cache reports total debt of $30.1M.
SVRA-DEBT-12838 Warrants outstanding: 48678005 90% xbrl warrant detail from xbrl 2026-03-31.

Savara Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Savara Inc..

Savara Inc. Ownership

HolderNameConfidenceEvidence
SVRA-OWNER-NEA-MANAGEMENT-COMPANY-LLC NEA Management Company, LLC 90% 13F overlay lists NEA Management Company, LLC as top holder; 187 tracked holders.

Savara Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
MAZE Maze Therapeutics, Inc. 100.00 2
MDGL Madrigal Pharmaceuticals, Inc. 100.00 2
SGHT Sight Sciences, Inc. 100.00 2
REPL Replimune Group, Inc. 100.00 2
OBIO Orchestra BioMed Holdings, Inc. 100.00 2
ALEC Alector, Inc. 100.00 2
TMO Thermo Fisher Scientific Inc. 100.00 1 ['supplier']
PHGE BiomX Inc. 100.00 2
RCUS Arcus Biosciences, Inc. 100.00 2
IRON Disc Medicine, Inc. 100.00 2
CMPS COMPASS Pathways plc 100.00 2
ALT Altimmune, Inc. 100.00 2
DYN Dyne Therapeutics, Inc. 100.00 2
VRDN Viridian Therapeutics, Inc. 100.00 2
BCYC Bicycle Therapeutics plc 100.00 2
ENGN enGene Therapeutics Inc. 100.00 2
KURA Kura Oncology, Inc. 100.00 2
WAT Waters Corporation 50.00 2
ICLR ICON Public Limited Company 50.00 2
CLLS Cellectis S.A. 50.00 2
View SVRA supply chain intel →

Explore the full interactive supply chain map for Savara Inc..

Open SVRA supply chain map →
ChainSifter · Guerilla Finance Terms Disclaimer ← Back to Map